Загрузка...
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
The primary aim of this study was to examine the effect of severe renal impairment (SRI) on the pharmacokinetics of lemborexant, a dual orexin receptor antagonist indicated for the treatment of insomnia. A phase 1 multicenter, single‐dose, open‐label, parallel‐group study was conducted in subjects w...
Сохранить в:
| Опубликовано в: : | Pharmacol Res Perspect |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7945683/ https://ncbi.nlm.nih.gov/pubmed/33689224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.734 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|